Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study

NCT06962189 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06962189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06962189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 15, 2025
Completion date
December 31, 2028
Enrollment
39 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer (stage iii)